News | Cardiovascular Ultrasound | September 04, 2019

Global Echocardiography Normal Values Study Presented at European Society of Cardiology Congress

WASE Normal Values Study data focuses on defining normal values of 2-D left ventricular dimensions, volume and function across different races and nations

Global Echocardiography Normal Values Study Presented at European Society of Cardiology Congress

September 4, 2019 — Final data from the World Alliance Societies of Echocardiography (WASE) Normal Values Study was presented as part of the late-breaking science at the European Society of Cardiology (ESC) Congress, Aug. 31-Sept. 4 in Paris, France. The data presented focuses specifically on 2-D left ventricular dimensions, volumes and function. 

The WASE Normal Values Study, which was launched in 2016, is unique in that it provides normal reference values of echocardiographic parameters in adults across a wide range of age, race and ethnicity from 15 different countries. In contrast to previous studies, WASE included head-to-head inter-country and inter-race comparisons, in which all technical differences in data acquisition between regions were minimized and standardized by using state-of-the-art equipment and strictly following the 2015 ASE and European Association of Cardiovascular Imaging (EACVI) updated recommendations for chamber quantification. In addition, data analysis and interpretation were conducted uniformly by a core-laboratory at MedStar Health Research Institute and the University of Chicago.

Federico M. Asch, M.D., FASE, MedStar Health Research Institute, Washington, D.C., and Roberto M. Lang, M.D., FASE, University of Chicago, served as co-principal investigators on this study. Asch, who presented the data at ESC, said, “The clinical usefulness of echocardiography is based on the detection of abnormalities, which relies on the accurate definition of “normality” across different countries or races. Currently, available echocardiographic ‘reference values’ that define ‘normality’ are mostly based on cross-sectional observations of Caucasians from the United States and Europe. The WASE study evaluated individuals from multiple countries and races with the aim of describing normative values that could be applied to the global community world-wide, and to determine differences and similarities among people from different countries and races. The current report focuses specifically on 2-D left ventricular dimensions, volumes, and function.”

In total, 2,008 subjects were enrolled in the study. The average age was 45, where 42.8 percent were of White race, 41.8 percent Asian and 9.7 percent Black. Results indicated that left ventricular (LV) dimensions and volumes are larger in males, while left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) are higher in females. Global WASE normal ranges for LV dimensions were similar to those in the ASE/EACVI guidelines, but the upper limits of normal for LV volumes and the lower limits of normal for LVEF were higher in WASE study participants in all countries. 

Significant inter-country variation was identified for all left ventricular parameters reflecting LV size (dimensions, mass and volumes) even after indexing to body surface area (BSA), with left ventricular end-diastolic volume and left ventricular global systolic function having the highest variation. The largest volumes were noted in Australia, while the smallest were measured in India for both genders. While there were no differences in LV size between individuals of White and Black race, the LV of Asians and Mixed (mostly Mexicans mix of White and native American) were smaller. However, within each race group, there were significant inter-country variations. This finding suggests that in addition to gender and BSA, specific country should be considered when evaluating LV volumes. Inter-country variation for LVEF and GLS was smaller, but still statistically significant.

In conclusion, this study points out that current guideline-recommended normal ranges for LV volumes and EF should be adjusted. Inter-country variability is significant for LV volumes and therefore nationality should be considered for defining ranges of normality. 

A manuscript reporting these findings has been accepted for publication in the Journal of the American Society of Echocardiography will be published online later this month.

For more information: www.escardio.org

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init